Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial

This publication has 31 references indexed in Scilit:

• Racial disparities in Black men with prostate cancer: A literature review
  Cancer, 2022
• Cause of death during prostate cancer survivorship: A contemporary, US population–based analysis
  Cancer, 2021
• Fear of Recurrence in Prostate Cancer Patients: A Cross-sectional Study After Radical Prostatectomy or Active Surveillance
  European Urology Open Science, 2021
• Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
  Molecular Therapy, 2018
• Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer
  Journal of Radiation Oncology, 2015
• Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
  Cancer Immunology, Immunotherapy, 2015
• Final Report of Multicenter Canadian Phase III Randomized Trial of 3 Versus 8 Months of Neoadjuvant Androgen Deprivation Therapy Before Conventional-Dose Radiotherapy for Clinically Localized Prostate Cancer
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
• The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
• Enhanced Therapeutic Effect of HSV-tk+GCV Gene Therapy and Ionizing Radiation for Prostate Cancer
  Molecular Therapy, 2001